Why the study?
Does atrial natriuretic peptide improve survival, dialysis-free survival, or renal function in patients with acute renal failure?
Does atrial natriuretic peptide improve survival, dialysis-free survival, or renal function in patients with acute renal failure?
Despite early promise, atrial natriuretic peptide does not provide clinically relevant benefits for survival or renal function in acute renal failure.
ANP should not be used in acute renal failure; leaves open whether related peptides merit targeted trials.
Atrial natriuretic peptide can increase glomerular filtration rate and filtration fraction and can promote natriuresis, effects that would logically seem to improve renal function after acute tubular necrosis from ischemic or toxic injury. Early human trials suggested a beneficial effect of atrial natriuretic peptide on creatinine clearance, and a reduction in the need for dialysis in treated patients. However, randomized, placebo-controlled trials have failed to show a clinically relevant benefit on survival, dialysis-free survival, or renal function in patients treated with this agent.
No takes yet. Share an insight, caveat, or question.
Brenner et al. (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: